We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold Integra Stock in Your Portfolio Now?
Read MoreHide Full Article
Key Takeaways
IART stock has plunged 60% in a year, far worse than the industry's 8.5% decline.
Integra sees strong CSS demand, with double-digit growth from CereLink, MAYFIELD Capital and Aurora.
IART is expanding globally with product launches and approvals across Europe, Japan and China.
Integra LifeSciences Holdings Corporation (IART - Free Report) is seeing healthy demand for its industry-leading products within the Codman Specialty Surgical (“CSS”) segment. The company is also successfully expanding its international footprint through certain key developments in overseas markets. Yet, macroeconomic challenges and unfavorable liquidity raise concerns for Integra.
In the past year, this Zacks Rank #3 (Hold) stock has lost 60% compared with the industry’s 8.5% decline. The S&P 500 composite has risen 20.1% in the same time frame.
The renowned medical device company has a market capitalization of $719.8 million. Integra has an earnings yield of 25.1% against the industry’s yield of -0.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 7.7%.
Let’s delve deeper.
Tailwinds for IART Stock
Strong Prospects in CSS: Integra sees healthy demand for its industry-leading products within CSS. Integra is also upbeat about the recently closed 2025 acquisition of Acclarent, which positions the company as a leader in the ENT segments, expands addressable markets, and provides immediate scale and accretive growth to the CSS portfolio.
For the fourth quarter of 2025, the company delivered solid results, driven by double-digit performance in CereLink, MAYFIELD Capital and Aurora with above-market contributions from BactiSeal, DuraGen and CUSA. The company gains strength from sustained demand across the global neurosurgery market.
Within ENT, AERA Eustachian Tube Balloon Dilation system and TruDi Navigated Disposables experienced double-digit growth, while MicroFrance ENT instruments saw mid-single-digit gains. International markets remained a meaningful contributor to the CSS business led by double-digit performance in China and Canada.
In 2025, the company began enrollment in the Acclarent AERA Pediatric Registry, a prospective, multicenter observational study evaluating real-world use of the AERA Eustachian Tube Balloon Dilation system in children.
Solid Growth in International Business: Integra is successfully broadening its international footprint through certain key developments on the overseas front. During 2025 and 2024, several new products were introduced in select international markets, including MicroMatrix and Certas Plus Programmable Valve, which were launched in Europe, and CUSA Clarity laparoscopic tip, which was launched in Australia, New Zealand, Japan, Canada, South Africa and Israel. DuraGen Secure received approval in Japan, while DuraGen Plus and Certas Plus were approved in China.
Concerns for IART Stock
Tough Liquidity Position: Integra’s position looks quite tight from the liquidity point of view, having ended the fourth quarter of 2025 with net debt of $1.60 billion, and cash and cash equivalents of $264 million. The company has $127 million of current debt on its balance sheet. Debt-to-capital jumped to 63.5%. A times interest earned ratio of -5.5 suggests that Integra may face challenges in meeting its debt obligations.
Image Source: Zacks Investment Research
Choppy Macro Environment: Integra’s operations remain exposed to macroeconomic uncertainties, including supply-chain disruptions, inflation, escalation of wars and other armed conflicts, among others. These factors may reduce demand for its products and services, increase competition, and lead to lower sales volumes and downward pricing pressure, longer sales cycles and slower adoption of new technologies. In the fourth quarter, Integra’s sales declined on a year-over-year basis.
U.S. import tariffs and reciprocal measures by China are expected to raise the company’s cost of goods sold. In the fourth quarter, the company’s cost of goods sold increased 10.6% year over year.
IART Stock’s Estimate Trend
The Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has moved north 0.4% to $2.32 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $1.68 billion. This suggests a 2.7% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Edwards Lifesciences (EW - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 19.5% against the industry’s 3.7% decline over the past year.
Intuitive Surgical, sporting a Zacks Rank #1 at present, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have risen 1.5% against the industry’s 3.7% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.6% against the industry’s -0.7% yield. Shares of the company have climbed 23.2% against the industry’s 3.7% decline. EW’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 5.5%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Should You Continue to Hold Integra Stock in Your Portfolio Now?
Key Takeaways
Integra LifeSciences Holdings Corporation (IART - Free Report) is seeing healthy demand for its industry-leading products within the Codman Specialty Surgical (“CSS”) segment. The company is also successfully expanding its international footprint through certain key developments in overseas markets. Yet, macroeconomic challenges and unfavorable liquidity raise concerns for Integra.
In the past year, this Zacks Rank #3 (Hold) stock has lost 60% compared with the industry’s 8.5% decline. The S&P 500 composite has risen 20.1% in the same time frame.
The renowned medical device company has a market capitalization of $719.8 million. Integra has an earnings yield of 25.1% against the industry’s yield of -0.9%. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 7.7%.
Let’s delve deeper.
Tailwinds for IART Stock
Strong Prospects in CSS: Integra sees healthy demand for its industry-leading products within CSS. Integra is also upbeat about the recently closed 2025 acquisition of Acclarent, which positions the company as a leader in the ENT segments, expands addressable markets, and provides immediate scale and accretive growth to the CSS portfolio.
For the fourth quarter of 2025, the company delivered solid results, driven by double-digit performance in CereLink, MAYFIELD Capital and Aurora with above-market contributions from BactiSeal, DuraGen and CUSA. The company gains strength from sustained demand across the global neurosurgery market.
Within ENT, AERA Eustachian Tube Balloon Dilation system and TruDi Navigated Disposables experienced double-digit growth, while MicroFrance ENT instruments saw mid-single-digit gains. International markets remained a meaningful contributor to the CSS business led by double-digit performance in China and Canada.
In 2025, the company began enrollment in the Acclarent AERA Pediatric Registry, a prospective, multicenter observational study evaluating real-world use of the AERA Eustachian Tube Balloon Dilation system in children.
Solid Growth in International Business: Integra is successfully broadening its international footprint through certain key developments on the overseas front. During 2025 and 2024, several new products were introduced in select international markets, including MicroMatrix and Certas Plus Programmable Valve, which were launched in Europe, and CUSA Clarity laparoscopic tip, which was launched in Australia, New Zealand, Japan, Canada, South Africa and Israel. DuraGen Secure received approval in Japan, while DuraGen Plus and Certas Plus were approved in China.
Concerns for IART Stock
Tough Liquidity Position: Integra’s position looks quite tight from the liquidity point of view, having ended the fourth quarter of 2025 with net debt of $1.60 billion, and cash and cash equivalents of $264 million. The company has $127 million of current debt on its balance sheet. Debt-to-capital jumped to 63.5%. A times interest earned ratio of -5.5 suggests that Integra may face challenges in meeting its debt obligations.
Image Source: Zacks Investment Research
Choppy Macro Environment: Integra’s operations remain exposed to macroeconomic uncertainties, including supply-chain disruptions, inflation, escalation of wars and other armed conflicts, among others. These factors may reduce demand for its products and services, increase competition, and lead to lower sales volumes and downward pricing pressure, longer sales cycles and slower adoption of new technologies. In the fourth quarter, Integra’s sales declined on a year-over-year basis.
U.S. import tariffs and reciprocal measures by China are expected to raise the company’s cost of goods sold. In the fourth quarter, the company’s cost of goods sold increased 10.6% year over year.
IART Stock’s Estimate Trend
The Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has moved north 0.4% to $2.32 in the past 30 days.
The consensus estimate for the company’s 2026 revenues is pegged at $1.68 billion. This suggests a 2.7% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Intuitive Surgical (ISRG - Free Report) and Edwards Lifesciences (EW - Free Report) .
Globus Medical has an earnings yield of 4.9%, well ahead of the industry’s -0.7% yield. Its earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 18.8%. The company’s shares have rallied 19.5% against the industry’s 3.7% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical, sporting a Zacks Rank #1 at present, has an earnings yield of 2.1% against the industry’s -0.7% yield. Shares of the company have risen 1.5% against the industry’s 3.7% decline. ISRG’s earnings topped estimates in each of the trailing four quarters, the average surprise being 13.2%.
Edwards Lifesciences, carrying a Zacks Rank #2 (Buy) at present, has an earnings yield of 3.6% against the industry’s -0.7% yield. Shares of the company have climbed 23.2% against the industry’s 3.7% decline. EW’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 5.5%.